HUTCHMED China licenses HMPL-A830 to GSK in up-to $1.295B deal
HUTCHMED (China) has entered a global licensing agreement with GSK for HMPL-A830, aiming to accelerate development and validate its ATTC platform. Deal terms include up to $1.295 billion in potential payments plus tiered royalties.
A global licensing deal with GSK for HMPL-A830, a first-in-class KRAS-EGFR ATTC asset, aims to accelerate global development and validate the ATTC platform.
The agreement includes up to $1.295 billion in potential payments and tiered royalties, while recent positive Phase III results support furthe…